Roche lung cancer drug gets FDA priority review

May 07, 2018

Roche Holding announced that the U.S. FDA has granted its drug, Tecentriq, priority review for the first-line treatment of a type of lung cancer.

Tecentriq is currently FDA approved for the treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC) who have disease progression following chemotherapy. The FDA has now granted priority review for Tecentriq in combination with Avastin (bevacizumab), paclitaxel and chemotherapy, for the initial treatment of people with metastatic non-squamous NSCLC.

The FDA is expected to make a decision on approval by September 5, 2018.

Read the press release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments